ArQule, Inc. (ARQL): Price and Financial Metrics
ARQL Stock Summary
- ARQL's price/sales ratio is 505.69; that's higher than the P/S ratio of 99.33% of US stocks.
- Over the past twelve months, ARQL has reported earnings growth of 181.01%, putting it ahead of 93.26% of US stocks in our set.
- As for revenue growth, note that ARQL's revenue has grown -79.08% over the past 12 months; that beats the revenue growth of merely 1.39% of US companies in our set.
- Stocks that are quantitatively similar to ARQL, based on their financial statements, market capitalization, and price volatility, are QURE, GERN, KDMN, ADAP, and ETON.
ARQL Stock Price Chart More Charts
ARQL Price/Volume Stats
|Current price||$20.00||52-week high||$20.45|
|Prev. close||$19.97||52-week low||$3.15|
|Day high||$20.00||Avg. volume||5,269,080|
|50-day MA||$14.57||Dividend yield||N/A|
|200-day MA||$9.89||Market Cap||2.42B|
ArQule, Inc. (ARQL) Company Bio
ArQule, Inc., a clinical-stage biotechnology company, researches and develops therapeutics for the treatment of cancer and rare diseases. The company was founded in 1993 and is based in Burlington, Massachusetts.